DMD and Duchenne muscular dystrophy: CRISPR/Cas9 components administered via adeno-associated viral vectors of serotype 9 (AAV9) resulted inre-framed dystrophin (DMDΔ51-52) expression in muscles, amelioration of DMD phenotype and survival [96].